Agios Pharm Net Worth
Agios Pharm Net Worth Breakdown | AGIO |
Agios Pharm Net Worth Analysis
Agios Pharm's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Agios Pharm's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Agios Pharm's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Agios Pharm's net worth analysis. One common approach is to calculate Agios Pharm's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Agios Pharm's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Agios Pharm's net worth. This approach calculates the present value of Agios Pharm's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Agios Pharm's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Agios Pharm's net worth. This involves comparing Agios Pharm's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Agios Pharm's net worth relative to its peers.
Enterprise Value |
|
To determine if Agios Pharm is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Agios Pharm's net worth research are outlined below:
| The company reported the previous year's revenue of 26.82 M. Net Loss for the year was (352.09 M) with profit before overhead, payroll, taxes, and interest of 12.54 M. | |
| Agios Pharm currently holds about 819.31 M in cash with (296.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.95. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors |
Agios Pharm uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Agios Pharm. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Agios Pharm's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Agios Pharm's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Agios Pharm is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Agios Pharm backward and forwards among themselves. Agios Pharm's institutional investor refers to the entity that pools money to purchase Agios Pharm's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.2 M | Bvf Inc | 2024-09-30 | 1.2 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.1 M | Rock Springs Capital Management Lp | 2024-06-30 | 1 M | Bnp Paribas Investment Partners Sa | 2024-06-30 | 911.2 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 882.7 K | Fisher Asset Management, Llc | 2024-09-30 | 855.3 K | Deutsche Bank Ag | 2024-06-30 | 662.2 K | Gw&k Investment Management, Llc | 2024-09-30 | 630.9 K | Farallon Capital Management, L.l.c. | 2024-09-30 | 5.7 M | Vanguard Group Inc | 2024-09-30 | 5.5 M |
Follow Agios Pharm's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.18 B.Market Cap |
|
Project Agios Pharm's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.36) | |
| Return On Capital Employed | (0.45) | (0.47) | |
| Return On Assets | (0.38) | (0.36) | |
| Return On Equity | (0.43) | (0.46) |
When accessing Agios Pharm's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Agios Pharm's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Agios Pharm's profitability and make more informed investment decisions.
Evaluate Agios Pharm's management efficiency
Agios Pharm has return on total asset (ROA) of (0.1818) % which means that it has lost $0.1818 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5366 %, meaning that it created $0.5366 on every $100 dollars invested by stockholders. Agios Pharm's management efficiency ratios could be used to measure how well Agios Pharm manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to grow to -0.36. In addition to that, Return On Capital Employed is likely to drop to -0.47. At this time, Agios Pharm's Non Current Assets Total are very stable compared to the past year. As of the 25th of November 2024, Non Currrent Assets Other is likely to grow to about 4.3 M, while Total Assets are likely to drop about 752.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 14.57 | 8.41 | |
| Tangible Book Value Per Share | 14.57 | 8.41 | |
| Enterprise Value Over EBITDA | (3.18) | (3.34) | |
| Price Book Value Ratio | 1.53 | 1.45 | |
| Enterprise Value Multiple | (3.18) | (3.34) | |
| Price Fair Value | 1.53 | 1.45 | |
| Enterprise Value | 1.2 B | 1.5 B |
The operational strategies employed by Agios Pharm management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 67.8871 | Revenue 32.9 M | Quarterly Revenue Growth 0.212 | Revenue Per Share 0.582 | Return On Equity 0.5366 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Agios Pharm insiders, such as employees or executives, is commonly permitted as long as it does not rely on Agios Pharm's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Agios Pharm insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Agios Pharm Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 13th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 26th of April 2024 Other Reports | ViewVerify |
Agios Pharm Earnings per Share Projection vs Actual
Agios Pharm Corporate Management
| DSc FRSC | CoFounder Board | Profile | |
| Dr DACVP | Consultant | Profile | |
| Sarah MD | Chief Development | Profile | |
| James Burns | Corporate Officer | Profile | |
| Clive Patience | Chief Officer | Profile | |
| ShinSan Su | CoFounder Board | Profile | |
| Brian MBA | CEO Director | Profile |
Already Invested in Agios Pharm?
The danger of trading Agios Pharm is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Agios Pharm is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Agios Pharm. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Agios Pharm is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 11.66 | Revenue Per Share 0.582 | Quarterly Revenue Growth 0.212 | Return On Assets (0.18) | Return On Equity 0.5366 |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.